Clinical trials: Plaque Control
Psoriasis
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B).
- Trial name
- NCT01782664
- Testing
- 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Psoriasis
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- PSTELLAR (NCT01550744)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 40 sites in United States
- Volunteers
- 478 people
- Sponsor
- Janssen Biotech, Inc.
Psoriasis
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
efficacy study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206387
- Testing
- Desoximetasone Spray 0.25%
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Chronic Plaque Psoriasis
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs.
- Trial name
- BELIEVE (NCT00574249)
- Testing
- adalimumab, Calcipotriol/Betamethasone Ointment
- Where
- 131 sites in Austria, Belgium and 13 more
- Volunteers
- 730 people
- Sponsor
- Abbott
Psoriasis Vulgaris
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.
- Trial name
- NCT02193815
- Testing
- PF06263276, Vehicle, 2%Tofacitinib Ointment
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Gingivitis
A Clinical Study to Evaluate the Efficacy of a Range of Dental/Denture Products for Improved Oral Health in Partial Denture Wearers
The purpose of this study is to investigate the effectiveness of usage of a range of oral products (toothpaste, mouth rinse, denture cleanser) on the oral health of partial denture wearers compared to existing oral hygiene…
- Trial name
- NCT04290624
- Testing
- Experimental Dentifrice: Stannous Fluoride, COREGA Denture Foaming Cleanser, Mouth rinse: Sodium Fluoride
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- HALEON
Plaque Psoriasis
Safety and Efficacy Study of CF101 to Treat Psoriasis
This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis.
- Trial name
- NCT00428974
- Testing
- CF101 1mg, CF101 2mg, CF101 4mg
- Where
- 4 sites in Israel
- Volunteers
- 76 people
- Sponsor
- Can-Fite BioPharma
Psoriasis
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.
- Trial name
- NCT02872285
- Testing
- Drug: LYC-30937-EC
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lycera Corp.
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plaque Psoriasis
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 1 (NCT05223868)
- Testing
- JNJ-77242113
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 255 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer
Plaque Psoriasis, Skin Diseases
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
- Trial name
- CLEAR-PS (NCT03358290)
- Testing
- JTE-051
- Where
- 16 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Shionogi Inc.
Psoriasis, Plaque Psoriasis
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
- Trial name
- NCT04603027
- Testing
- EDP1815
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 249 people
- Sponsor
- Evelo Biosciences, Inc.
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Plaque Psoriasis
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06602219
- Testing
- LY4100511
- Where
- 58 sites in United States, Canada and 5 more
- Volunteers
- 222 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company